Hypercalcemia of Malignancy

Hypercalcemia is the most common life-threatening metabolic disorder associated with cancer. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.

Inhalt

Biological Aspects.- Cytokines as Mediators of Hypercalcemia of Malignancy.- Humoral Hypercalcemia of Malignancy: Role of Parathyroid Hormone-Related Protein.- In Vivo Models of Hypercalcemia of Malignancy.- Morphological Characteristics of Tumors with Humoral Hypercalcemia of Malignancy: Functional Morphology of PTHrP.- Clinical Aspects.- Epidemiological Aspects of Hypercalcemia of Malignancy.- Clinical Picture of Humoral Hypercalcemia of Malignancy.- Hypercalcemia Associated with Hematologic Malignancies.- Differential Diagnosis of Hypercalcemia: Laboratory Assessment.- Drug Therapy of Hypercalcemia Due to Malignancy.